Company intelligence / Profile preview

Neuronix

Yoqneam, Haifa District, Israelneuronix.com ↗

Ownership: Private
Development stage: Other

Overview

Neuronix has developed the neuroAD Therapy System—a non-invasive medical device that combines transcranial magnetic stimulation with computer-based cognitive training for treating mild to moderate Alzheimer’s disease. The system is CE-marked and commercially available in Europe, Israel, and parts of Asia/Australia. Multiple clinical studies have been published supporting its efficacy; over 400 subjects have participated across different clinical settings. In the US, it remains investigational pending FDA approval[1][2][4].

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

None publicly disclosed.

Beyond the preview

Go deeper on Neuronix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuronix.

Explore the full profile